Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Rectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Triple Negative Breast Neoplasms 1Solid Tumor 1MSI-H 1Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 59Carboplatin 56Pemetrexed 47Cisplatin 39Paclitaxel 24Nivolumab 23Docetaxel 21durvalumab 20Gemcitabine 15130-nm albumin-bound paclitaxel 14osimertinib 13Cetuximab 12Specimen Handling 11Magnetic Resonance Spectroscopy 11atezolizumab 10amivantamab 8Taxes 8Radiotherapy 8Radiosurgery 7Ipilimumab 7lazertinib 6alectinib 6Ramucirumab 6Observation 6Bevacizumab 6cemiplimab 5Leucovorin 5Fluorouracil 5Etoposide 5Erlotinib Hydrochloride 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma, Non-Small-Cell Lung × sintilimab × 30 days × Clear all
NCT05549037 2026-06-03

LungTIME-C01

Hunan Province Tumor Hospital

Phase 3 Completed
210 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07603661 2026-05-22

Sintilimab Plus Chemotherapy as Induction Therapy for Unresectable Stage IIIC NSCLC

Sun Yat-sen University

Phase 2 Not yet recruiting
33 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡